Acutaas Chemicals delivered robust Q2 FY26 performance, with revenue up 24.1% year-on-year to ₹306.2 Cr.

This growth was primarily fueled by strong demand in Advanced Pharmaceutical Intermediates and steady contributions from Specialty Chemicals.

For the half-year, revenue climbed 21% to ₹513.4 Cr.

Profitability soared, with Q2 EBITDA jumping 94.8% to ₹95.3 Cr (31.1% margin), and PAT rocketing 91.3% to ₹71.9 Cr (23.5% margin). These gains stemmed from cost improvements, a favorable product mix, and operating leverage.

H1 figures also impressed, with EBITDA up 86% to ₹146.2 Cr and PAT up 122% to ₹115.9 Cr.

The company's market cap stands at ₹10,789 Cr.

Strategically, Acutaas is expanding into high-growth areas like Battery Chemicals and Semiconductors, strengthening global partnerships for sustainable long-term business.

Management anticipates approximately 25% revenue growth for the full year, confident in its strategic direction.